180 results
Search Results
2. Mitochondrial control of antigen presentation in cancer cells.
3. Tracking down tumor-specific T cells.
4. Sticking it to KRAS: Covalent Inhibitors Enter the Clinic
5. Meet the authors: Dr. Clint Allen and Dr. Sandro Santagata.
6. Breaching B cell tolerance in the tumor microenvironment.
7. An intimate encounter: DC3s empower anti-tumor CTLs.
8. Using real-word data to evaluate the effects of broadening eligibility criteria in oncology trials.
9. Intratumoral bacteria generate a new class of therapeutically relevant tumor antigens in melanoma.
10. Cancer Patients and Risk of Mortality for COVID-19.
11. Cancer-Type-Specific Bacteria: Freeloaders or Partners?
12. IRS-1: Auditing the effectiveness of mTOR inhibitors
13. Improving immunotherapy response through the use of designer bacteria.
14. Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and CHAARTED Studies.
15. Cancer and Apoptosis: Who Is Built to Last?
16. Personalized Medicine: Patient-Predictive Panel Power
17. Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR
18. Mutant BRAF Melanomas—Dependence and Resistance
19. Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
20. Seeking Cellular Fitness and Immune Evasion: Autophagy in Pancreatic Carcinoma.
21. BuCy RAFs drive cells into MEK addiction
22. Lost in translation: Dysregulation of cap-dependent translation and cancer
23. Connecting estrogen receptor function, transcriptional repression, and E-cadherin expression in breast cancer
24. CD103+ Dendritic Cells Producing Interleukin-12 in Anticancer Immunosurveillance.
25. Focal Gains of VEGFA: Candidate Predictors of Sorafenib Response in Hepatocellular Carcinoma.
26. A Novel Bullet Hits the Proteasome.
27. Tetraploidy and tumor development
28. Releasing the Block: Setting Differentiation Free with Mutant IDH Inhibitors.
29. Interweaving the Strands: β-Catenin, an HIV Co-Receptor, and Schwann Cell Tumors
30. Growth Factor Receptors Define Cancer Hierarchies
31. EMT and MET in Metastasis: Where Are the Cancer Stem Cells?
32. PI3King on MYCN to Improve Neuroblastoma Therapeutics
33. How to Fool a Wonder Drug: Truncate and Dimerize
34. “Ring-Fencing” BRCA1 Tumor Suppressor Activity
35. Discovery of a Secreted Tumor Suppressor Provides a Promising Therapeutic Strategy for Follicular Lymphoma
36. The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment
37. Loss of 53BP1 Is a Gain for BRCA1 Mutant Cells
38. The Raf Inhibitor Paradox: Unexpected Consequences of Targeted Drugs
39. DUB-le Trouble for Cell Survival
40. PARsing the Phrase “All in for Axin”— Wnt Pathway Targets in Cancer
41. How Much REST Is Enough?
42. VHL Inactivation: A New Road to Senescence
43. A Catalytic Role for Proangiogenic Marrow-Derived Cells in Tumor Neovascularization
44. Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?
45. FGF Signaling in Prostate Tumorigenesis—New Insights into Epithelial-Stromal Interactions
46. Multiple Myeloma: Lusting for NF-κB
47. Inflammatory Tales of Liver Cancer
48. Rb Loss Causes Cancer by Driving Mitosis Mad
49. Radiation resistance and stem-like cells in brain tumors
50. Can't kick that oncogene habit
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.